{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:59:07Z","timestamp":1790823547467,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["RVO 00023728"],"award-info":[{"award-number":["RVO 00023728"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["BBMRICZ LM2023033"],"award-info":[{"award-number":["BBMRICZ LM2023033"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["RVO VFN64165"],"award-info":[{"award-number":["RVO VFN64165"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["MHCZ-DRO FNOL 00098892"],"award-info":[{"award-number":["MHCZ-DRO FNOL 00098892"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NU22\\u201301-00465"],"award-info":[{"award-number":["NU22\\u201301-00465"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["IGA_LF_2023_002"],"award-info":[{"award-number":["IGA_LF_2023_002"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.vph.2025.107495","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T14:49:38Z","timestamp":1744728578000},"page":"107495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Ceramide-based risk score: A novel laboratory tool for cardiovascular risk stratification in hyperuricemia and gout"],"prefix":"10.1016","volume":"159","author":[{"given":"Ale\u0161","family":"Kvasni\u010dka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Friedeck\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbora","family":"Piskl\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Rozhon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pavelka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanka","family":"Stib\u016frkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2025.107495_bb0005","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1016\/S2665-9913(23)00338-7","article-title":"Gout and incidence of 12 cardiovascular diseases: a case-control study including 152 663 individuals with gout and 709 981 matched controls","volume":"6","author":"Ferguson","year":"2024","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.vph.2025.107495_bb0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-015-0522-8","article-title":"Epidemiology and management of gout in Taiwan: a nationwide population study","volume":"17","author":"Kuo","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.vph.2025.107495_bb0015","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/acr.23706","article-title":"Patients with early-onset gout and development of earlier severe joint involvement and metabolic comorbid conditions: results from a cross-sectional epidemiologic survey","volume":"71","author":"Pascart","year":"2019","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.vph.2025.107495_bb0020","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.vph.2025.107495_bb0025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13075-023-03204-6","article-title":"Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment","volume":"25","author":"Kvasni\u010dka","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.vph.2025.107495_bb0030","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.atherosclerosis.2015.10.022","article-title":"Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: results of the ATHEROREMO-IVUS study","volume":"243","author":"Cheng","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2025.107495_bb0035","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1161\/ATVBAHA.116.307497","article-title":"Circulating ceramides predict cardiovascular outcomes in the population-based FINRISK 2002 cohort","volume":"36","author":"Havulinna","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2025.107495_bb0040","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cca.2020.10.005","article-title":"Ceramides improve atherosclerotic cardiovascular disease risk assessment beyond standard risk factors","volume":"511","author":"Meeusen","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.vph.2025.107495_bb0045","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/eurheartj\/ehw148","article-title":"Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol","volume":"37","author":"Laaksonen","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2025.107495_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.570628","article-title":"Ceramides and ceramide scores: clinical applications for cardiometabolic risk stratification","volume":"11","author":"Hilvo","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.vph.2025.107495_bb0055","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1007\/s00216-016-9425-z","article-title":"Development and validation of a high-throughput LC-MS\/MS assay for routine measurement of molecular ceramides","volume":"408","author":"Kauhanen","year":"2016","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.vph.2025.107495_bb0060","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction","volume":"367","author":"Kaptoge","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2025.107495_bb0065","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0009-9120(01)00263-6","article-title":"The plasma parameter log (TG\/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL))","volume":"34","author":"Dobi\u00e1sov\u00e1","year":"2001","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.vph.2025.107495_bb0070","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1161\/HYPERTENSIONAHA.121.17555","article-title":"Serum urate trajectory in young adulthood and incident cardiovascular disease events by middle age: CARDIA study","volume":"78","author":"Morikawa","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2025.107495_bb0075","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12872-019-1215-z","article-title":"Serum uric acid and risk of cardiovascular mortality: a systematic review and dose-response meta-analysis of cohort studies of over a million participants","volume":"19","author":"Rahimi-Sakak","year":"2019","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.vph.2025.107495_bb0080","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1038\/s41588-024-02017-w","article-title":"Publisher correction: a genome-wide association analysis reveals new pathogenic pathways in gout","volume":"56","author":"Major","year":"2024","journal-title":"Nat. Genet."},{"key":"10.1016\/j.vph.2025.107495_bb0085","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41569-021-00536-1","article-title":"Ceramides and other sphingolipids as drivers of cardiovascular disease","volume":"18","author":"Choi","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.vph.2025.107495_bb0090","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2021.04.021","article-title":"Circulating ceramides as biomarkers of cardiovascular disease: evidence from phenotypic and genomic studies","volume":"327","author":"McGurk","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2025.107495_bb0095","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/ATVBAHA.116.305675","article-title":"Sphingolipids contribute to human atherosclerotic plaque inflammation","volume":"36","author":"Edsfeldt","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189125000345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189125000345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T23:05:33Z","timestamp":1748905533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189125000345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":19,"alternative-id":["S1537189125000345"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2025.107495","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceramide-based risk score: A novel laboratory tool for cardiovascular risk stratification in hyperuricemia and gout","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2025.107495","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107495"}}